ClinicalTrials.gg
CompletedNCT01812707Updated Oct 4, 2016Results posted

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan

A Phase 2 interventional study of Alirocumab and Placebo (for alirocumab) in Hypercholesterolemia, sponsored by Sanofi. Completed at 4 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-10-04.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
24th of 43
100 · median 107
Started
2013
with 5 others
Phase 2
9 of 43
none open now
Registered
22nd of 43
by date
Lead sponsor
28 of 43
Sanofi

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 24th largest by enrollment, is one of 6 that started in 2013, is one of 9 in phase 2, and was the 22nd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9).

Primary Objective of the study:

To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 12 weeks of treatment in comparison with placebo in participants with LDL-C ≥100 mg/dL (≥2.59 mmol/L) on ongoing stable atorvastatin therapy.

Secondary Objectives:

  • To evaluate the effects of alirocumab on other lipid levels after 12 weeks of treatment in comparison with placebo
  • To evaluate the safety and tolerability of alirocumab
  • To evaluate the development of anti-alirocumab antibodies
  • To evaluate the pharmacokinetics of alirocumab
Read the detailed description

The duration of study participation depended on the status of the participant at screening: 21 to 27 weeks including a screening/run-in period of 1 to 7 weeks, a double-blind treatment period of 12 weeks, followed by an 8-week follow-up period.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with primary hypercholesterolemia treated with atorvastatin at stable dose of 5-20 mg for at least 6 weeks prior to screening and likely to have LDL-C ≥100 mg/dL (≥2.59 mmol/L) at the screening visit.

OR

  • Participants with primary hypercholesterolemia who were receiving a lipid-lowering treatment other than atorvastatin, or who were not at stable dose of atorvastatin 5-20 mg for at least 6 weeks prior to screening if they were likely to have LDL-C ≥100 mg/dL (≥2.59 mmol/L) after a 6-week run-in treatment period on atorvastatin therapy.

Exclusion criteria

Exclusion criteria:

  1. LDL-C \<100 mg/dL (\<2.59 mmol/L)

    • at screening visit for participants who were being treated with stable dose of atorvastatin 5-20 mg for at least 6 weeks prior to screening OR
    • at the end of the 6-week run-in period on atorvastatin for participants receiving a lipid lowering treatment other than atorvastatin, or not at stable dose of atorvastatin 5-20 mg for at least 6 weeks prior to screening
  2. Participants with type 1 diabetes
  3. Participants with type 2 diabetes treated with insulin, or without, and considered poorly controlled at screening.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo (for alirocumab) every 2 weeks (Q2W) for 12-weeks in combination with atorvastatin stable dose.

    Drug: Placebo (for alirocumab) · Drug: Atorvastatin

  • Experimental
    Alirocumab 50 mg Q2W

    Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.

    Drug: Alirocumab · Drug: Atorvastatin

  • Experimental
    Alirocumab 75 mg Q2W

    Alirocumab 75 mg Q2W for 12-weeks in combination with atorvastatin stable dose.

    Drug: Alirocumab · Drug: Atorvastatin

  • Placebo comparator
    Alirocumab 150 mg Q2W

    Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.

    Drug: Alirocumab · Drug: Atorvastatin

Interventions

  • Two SC injections in the abdomen only

    Also known as: SAR236553, RGEN727

  • DrugPlacebo (for alirocumab)

    Two subcutaneous (SC) injections in the abdomen only Route of administration: subcutaneous injection (1 mL) in the abdomen

  • Orally once daily at a stable dose of 5 to 20 mg as background therapy Route of administration: oral administration in the evening

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis

    Calculated LDL-C values were obtained using the Friedewald formula. Baseline adjusted least squares (LS) means and standard errors were estimated using an analysis of covariance (ANCOVA) model including available post-baseline data on treatment from first investigational product (IP) injection up to 21 days after last IP injection (on-treatment analysis). Missing Week 12 data were imputed by last observation carried forward \[LOCF\] method.

    Time frame: Baseline to Week 12 (LOCF)

Secondary outcomes

  1. Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis

    Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

    Time frame: Baseline to Week 12 (LOCF)

  2. Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis

    Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

    Time frame: Baseline to Week 12 (LOCF)

  3. Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and < 70 mg/dL (1.81 mmol/L) at Week 12 - On-Treatment Analysis

    Time frame: Week 12 (LOCF)

  4. Percent Change From Baseline in Total Cholesterol, High-Density Lipoprotein Cholesterol (HDL-C), Non-HDL-C, and Apolipoprotein B (Apo-B) at Week 12 - On-Treatment Analysis

    Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

    Time frame: Baseline to Week 12 (LOCF)

  5. Percent Change From Baseline in Fasting Triglycerides and Lipoprotein (a) at Week 12 - On-Treatment Analysis

    Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameters, percent changes were expressed as median (inter-quartile range).

    Time frame: Baseline to Week 12 (LOCF)

  6. Absolute Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) Ratio at Week 12 - On-Treatment Analysis

    Adjusted LS mean and standard errors were estimated using the same ANCOVA as for primary endpoint.

    Time frame: From Baseline to Week 12 (LOCF)

07

Results

Posted Sep 24, 2015

Participant flow

The study was conducted at 4 centers in Japan. Overall, 162 participants were screened between March 2013 and August 2013, 62 of whom were run-in/screen failures, mainly due to exclusion criteria met.

Participant flow — Overall Study
MilestonePlaceboAlirocumab 50 mg Q2WAlirocumab 75 mg Q2WAlirocumab 150 mg Q2W
Started25252525
Treated25252525
Completed23252523
Not completed2002
Withdrew: Adverse event0002
Withdrew: Poor compliance to protocol1000
Withdrew: Consent withdrawn by participant1000

Outcome measures

PrimaryPercent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis

Calculated LDL-C values were obtained using the Friedewald formula. Baseline adjusted least squares (LS) means and standard errors were estimated using an analysis of covariance (ANCOVA) model including available post-baseline data on treatment from first investigational product (IP) injection up to 21 days after last IP injection (on-treatment analysis). Missing Week 12 data were imputed by last observation carried forward \[LOCF\] method.

Time frame:
Baseline to Week 12 (LOCF)
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis
percent changePlaceboAlirocumab 50 mg Q2WAlirocumab 75 mg Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis-2.7 ± 3.1-54.8 ± 3.1-62.3 ± 3.1-71.7 ± 3.1
Statistical analysis
  • Placebo vs Alirocumab 150 mg Q2W · ANCOVA · p = <0.0001 (Threshold for significance ≤0.05)
  • Placebo vs Alirocumab 75 mg Q2W · ANCOVA · p = <0.0001 (Threshold for significance ≤0.05)
  • Placebo vs Alirocumab 50 mg Q2W · ANCOVA · p = <0.0001 (Threshold for significance ≤0.05)
SecondaryAbsolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis

Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

Time frame:
Baseline to Week 12 (LOCF)
Reported as:
Least squares mean · mmol/L
Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis
mmol/LPlaceboAlirocumab 50 mg Q2WAlirocumab 75 mg Q2WAlirocumab 150 mg Q2W
Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis-0.1 ± 0.1-1.7 ± 0.1-1.9 ± 0.1-2.2 ± 0.1
SecondaryAbsolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis

Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

Time frame:
Baseline to Week 12 (LOCF)
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis
mg/dLPlaceboAlirocumab 50 mg Q2WAlirocumab 75 mg Q2WAlirocumab 150 mg Q2W
Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis-5.0 ± 3.6-67.1 ± 3.6-74.6 ± 3.6-85.8 ± 3.6
SecondaryPercentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and < 70 mg/dL (1.81 mmol/L) at Week 12 - On-Treatment Analysis
Time frame:
Week 12 (LOCF)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and < 70 mg/dL (1.81 mmol/L) at Week 12 - On-Treatment Analysis
percentage of participantsPlaceboAlirocumab 50 mg Q2WAlirocumab 75 mg Q2WAlirocumab 150 mg Q2W
LDL-C <100 mg/dL (2.59 mmol/L)8.0100.0100.0100.0
LDL-C < 70 mg/dL (1.81 mmol/L)0.084.084.088.0
SecondaryPercent Change From Baseline in Total Cholesterol, High-Density Lipoprotein Cholesterol (HDL-C), Non-HDL-C, and Apolipoprotein B (Apo-B) at Week 12 - On-Treatment Analysis

Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

Time frame:
Baseline to Week 12 (LOCF)
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol, High-Density Lipoprotein Cholesterol (HDL-C), Non-HDL-C, and Apolipoprotein B (Apo-B) at Week 12 - On-Treatment Analysis
percent changePlaceboAlirocumab 50 mg Q2WAlirocumab 75 mg Q2WAlirocumab 150 mg Q2W
Total Cholesterol-1.2 ± 2.1-31.9 ± 2.1-36.3 ± 2.1-41.4 ± 2.1
HDL-C-0.2 ± 2.05.1 ± 2.05.0 ± 2.03.2 ± 2.1
Non-HDL-C-0.9 ± 2.9-46.3 ± 2.9-53.1 ± 2.9-62.2 ± 2.9
Apo-B-2.3 ± 3.3-43.5 ± 3.3-48.6 ± 3.3-60.0 ± 3.3
SecondaryPercent Change From Baseline in Fasting Triglycerides and Lipoprotein (a) at Week 12 - On-Treatment Analysis

Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameters, percent changes were expressed as median (inter-quartile range).

Time frame:
Baseline to Week 12 (LOCF)
Reported as:
Median · percent change
Percent Change From Baseline in Fasting Triglycerides and Lipoprotein (a) at Week 12 - On-Treatment Analysis
percent changePlaceboAlirocumab 50 mg Q2WAlirocumab 75 mg Q2WAlirocumab 150 mg Q2W
Fasting Triglycerides1.3 (-13.1 to 22.5)-21.1 (-28.2 to 4.2)-10.7 (-25.0 to 6.5)-15.0 (-24.1 to 0.0)
Lipoprotein (a)-3.7 (-26.2 to 8.4)-35.6 (-52.5 to -7.5)-40.2 (-62.9 to -27.4)-43.3 (-69.4 to -14.2)
SecondaryAbsolute Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) Ratio at Week 12 - On-Treatment Analysis

Adjusted LS mean and standard errors were estimated using the same ANCOVA as for primary endpoint.

Time frame:
From Baseline to Week 12 (LOCF)
Reported as:
Least squares mean · ratio
Absolute Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) Ratio at Week 12 - On-Treatment Analysis
ratioPlaceboAlirocumab 50 mg Q2WAlirocumab 75 mg Q2WAlirocumab 150 mg Q2W
Absolute Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) Ratio at Week 12 - On-Treatment Analysis0.02 ± 0.02-0.30 ± 0.02-0.32 ± 0.02-0.38 ± 0.02

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 20) regardless of seriousness or relationship to investigational medicinal product (IMP).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/25 (4%)5/25 (20%)
Alirocumab 50 mg Q2W—0/25 (0%)11/25 (44%)
Alirocumab 75 mg Q2W—0/25 (0%)8/25 (32%)
Alirocumab 150 mg Q2W—1/25 (4%)9/25 (36%)
Most frequent serious events
Most frequent serious events
EventPlaceboAlirocumab 50 mg Q2WAlirocumab 75 mg Q2WAlirocumab 150 mg Q2W
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/250/250/251/25
VertigoEar and labyrinth disorders1/250/250/250/25
Most frequent other events
Most frequent other events
EventPlaceboAlirocumab 50 mg Q2WAlirocumab 75 mg Q2WAlirocumab 150 mg Q2W
NasopharyngitisInfections and infestations2/256/256/254/25
Injection site reactionGeneral disorders1/253/252/252/25
CystitisInfections and infestations1/250/250/252/25
Back painMusculoskeletal and connective tissue disorders1/252/250/251/25
Ligament sprainInjury, poisoning and procedural complications1/250/250/252/25

Baseline characteristics

Randomized population.

Age, Continuous
Age, Continuous(years)PlaceboAlirocumab 50 mg Q2WAlirocumab 75 mg Q2WAlirocumab 150 mg Q2WTotal
Mean58.6 ± 9.257.8 ± 12.356.3 ± 12.058.2 ± 8.857.7 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAlirocumab 50 mg Q2WAlirocumab 75 mg Q2WAlirocumab 150 mg Q2WTotal
Female1116121655
Male14913945
Low-Density Lipoprotein Cholesterol (LDL-C) in mmol/L
Low-Density Lipoprotein Cholesterol (LDL-C) in mmol/L(mmol/L)PlaceboAlirocumab 50 mg Q2WAlirocumab 75 mg Q2WAlirocumab 150 mg Q2WTotal
Mean3.13 ± 0.553.16 ± 0.433.13 ± 0.433.12 ± 0.423.14 ± 0.45
LDL-C in mg/dL
LDL-C in mg/dL(mg/dL)PlaceboAlirocumab 50 mg Q2WAlirocumab 75 mg Q2WAlirocumab 150 mg Q2WTotal
Mean121.0 ± 21.1122.2 ± 16.6120.9 ± 16.7120.5 ± 16.2121.2 ± 17.5
08

Study locations

4 sites
  • Investigational Site Number 392002
    Koganei-Shi, Japan
  • Investigational Site Number 392001
    Shinjuku-Ku, Japan
  • Investigational Site Number 392003
    Suita-Shi, Japan
  • Investigational Site Number 392004
    Suita-Shi, Japan
09

References and documents

Publications

  • Teramoto T, Kobayashi M, Uno K, Takagi Y, Matsuoka O, Sugimoto M, Inoue S, Minami F, Baccara-Dinet MT. Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies). Am J Cardiol. 2016 Jul 1;118(1):56-63. doi: 10.1016/j.amjcard.2016.04.011. Epub 2016 Apr 21. PubMed 27184170 ↗
  • Leiter LA, Tinahones FJ, Karalis DG, Bujas-Bobanovic M, Letierce A, Mandel J, Samuel R, Jones PH. Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Diabet Med. 2018 Dec;35(12):1742-1751. doi: 10.1111/dme.13817. Epub 2018 Oct 9. PubMed 30183102 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 1 year 8 months after primary completion. A results delay was requested in Jan 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2013
First posted
Mar 18, 2013
Start
Mar 2013
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Results delay requested
Jan 22, 2015
Results first posted
Sep 24, 2015
Last update
Oct 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01812707
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 18, 2013
Start date
Mar 2013
Primary completion
Jan 2014
Completion
Jan 2014
Results posted
Sep 24, 2015
Last update
Oct 4, 2016

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion